Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.

Original languageEnglish (US)
Pages (from-to)2121-2129
Number of pages9
JournalPediatric Nephrology
Volume23
Issue number12
DOIs
StatePublished - 2008

Fingerprint

Nephrogenic Fibrosing Dermopathy
Gadolinium
Contrast Media
Kidney
Acute Kidney Injury
Kidney Transplantation
Pediatrics

Keywords

  • Contrast agents
  • End-stage renal disease
  • Gadolinium
  • Kidney disease
  • Magnetic resonance imaging
  • Nephrogenic systemic fibrosis

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. / Penfield, Jeffrey G.

In: Pediatric Nephrology, Vol. 23, No. 12, 2008, p. 2121-2129.

Research output: Contribution to journalArticle

@article{eefe466326934a88ade7823c179d9ce4,
title = "Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents",
abstract = "Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.",
keywords = "Contrast agents, End-stage renal disease, Gadolinium, Kidney disease, Magnetic resonance imaging, Nephrogenic systemic fibrosis",
author = "Penfield, {Jeffrey G.}",
year = "2008",
doi = "10.1007/s00467-008-0862-6",
language = "English (US)",
volume = "23",
pages = "2121--2129",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents

AU - Penfield, Jeffrey G.

PY - 2008

Y1 - 2008

N2 - Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.

AB - Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.

KW - Contrast agents

KW - End-stage renal disease

KW - Gadolinium

KW - Kidney disease

KW - Magnetic resonance imaging

KW - Nephrogenic systemic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=55649120234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649120234&partnerID=8YFLogxK

U2 - 10.1007/s00467-008-0862-6

DO - 10.1007/s00467-008-0862-6

M3 - Article

C2 - 18543004

AN - SCOPUS:55649120234

VL - 23

SP - 2121

EP - 2129

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 12

ER -